ICDs (implantable cardioverter defibrillators) coverage: Medicare extends comment period:
This article was originally published in Clinica
Medicare's administrators have extended the public comment period on the health plan's coverage policy for implantable cardioverter defibrillators from June 23 to July 23, the Centers for Medicare & Medicaid Services (CMS) has announced. The additional time will give manufacturers and hospitals time to comment on three new questions recently posed by the agency: What is the evidence surrounding the necessity of threshold testing at the time of implantation? What is the evidence of benefits and risks of adding anti-tachycardia pacing to the function of an implantable defibrillator, including the risk of an additional lead? And finally, is there sufficient scientific justification for the development of an ICD patient registry to collect information to better identify predictors of ICD firing for ventricular fibrillation (as a proxy for sudden cardiac death)?
You may also be interested in...
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.